admin – Page 2370 – Get News Story

Cytomegalovirus Infection Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Cytomegalovirus (CMV) Infection Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Cytomegalovirus (CMV) Infection pipeline landscape. It covers the Cytomegalovirus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cytomegalovirus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cytomegalovirus Infection Treatment Landscape @ Cytomegalovirus Infection Pipeline Outlook

Key Takeaways from the Cytomegalovirus Infection Pipeline Report

In August 2025, ModernaTX, Inc. announced a study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants. The purpose of the Phase 3 extension substudy is to extend the observation period of the main study and to assess the longer-term immunogenicity, efficacy, and safety of the mRNA-1647 vaccine against primary CMV infection in healthy females who were CMV-seronegative at Baseline of the mRNA-1647-P301 main study (including participants who remain CMV-seronegative upon entry into the extension substudy and participants who seroconverted during the main study).
In August 2025, Memorial Sloan Kettering Cancer Center conducted a study is to determine of letermovir (LTC) is effective at preventing Cytomegalovirus (CMV) infection from returning in people who have already had CMV infection after a bone marrow transplant.
DelveInsight’s Cytomegalovirus Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Cytomegalovirus Infection treatment.
The leading Cytomegalovirus Infection Companies such as Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
Promising Cytomegalovirus Infection Pipeline Therapies such as Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.

Discover groundbreaking developments in Cytomegalovirus Infection Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Cytomegalovirus Infection Clinical Trials Assessment

Cytomegalovirus Infection Emerging Drugs Profile

mRNA-1647: ModernaTX, Inc.

mRNA-1647 comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex and one mRNA encodes the Glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is important for CMV entry into a variety of cells, including epithelial cells, while gB is important for entry into all susceptible cells including fibroblasts. A vaccine that produces an immune response against both pentamer and gB has the potential to prevent CMV entry into a range of target cell types and thus prevent primary and congenital infections. Unlike a protein-based vaccine, mRNA-1647 instructs the body’s own cells to manufacture the antigens, resulting in functional antigens that mimic those presented to the immune system by CMV during a natural infection. Preclinical data previously published in Vaccine showed that vaccination with mRNA-1647 in animal models elicited potent and durable neutralizing antibody titers. Currently, the drug is in Phase III stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

Cytomegalovirus vaccine (Triplex) : Helocyte

The Triplex vaccine by Helocyte is a multi-antigen vaccine designed to induce a robust and durable virus-specific T-cell response against cytomegalovirus (CMV) infections, particularly in recipients of allogeneic hematopoietic stem cell transplants (HSCT) and solid organ transplants (SOT). The vaccine utilizes the Modified Vaccinia Ankara (MVA) vector to express three immunodominant CMV proteins: UL83 (pp65), UL123 (IE1), and UL122 (IE2). By targeting these proteins, Triplex stimulates a host antiviral response, enhancing both CD4+ and CD8+ T-cell responses. This mechanism of action helps control CMV infections by promoting cellular immunity, which is crucial for managing and preventing CMV-related complications in immunocompromised patients.. Currently, the drug is in Phase II stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

VBI-1501: VBI Vaccines Inc.

VBI-1501 by VBI Vaccines Inc. is a prophylactic cytomegalovirus (CMV) vaccine candidate developed using the company’s proprietary enveloped virus-like particle (eVLP) technology. This vaccine presents a modified form of the glycoprotein B (gB) found on CMV, which plays a crucial role in viral entry into host cells. The mechanism of action (MOA) of VBI-1501 involves inducing protective CMV-neutralizing antibodies that can block infection in multiple cell types, including fibroblasts and epithelial cells. By eliciting these antibodies, VBI-1501 aims to prevent CMV infection by mimicking the natural immune response observed in individuals who have developed immunity through natural infection. Currently, the drug is in Phase I stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

The Cytomegalovirus Infection Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
Cytomegalovirus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market

Stay informed about the Cytomegalovirus Infection pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Cytomegalovirus Infection Unmet Needs

Cytomegalovirus Infection Companies

Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.

Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Cytomegalovirus Infection Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Transform your understanding of the Cytomegalovirus Infection Pipeline! See the latest progress in drug development and clinical research @ Cytomegalovirus Infection Market Drivers and Barriers, and Future Perspectives

Scope of the Cytomegalovirus Infection Pipeline Report

Coverage- Global
Cytomegalovirus Infection Companies- Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
Cytomegalovirus Infection Pipeline Therapies- Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.
Cytomegalovirus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Cytomegalovirus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Infectious Diseases Research–Access the Full Cytomegalovirus Infection Pipeline Analysis Today! @ Cytomegalovirus Infection Drugs and Companies

Table of Contents

Introduction
Executive Summary
Cytomegalovirus (CMV) Infection: Overview
Pipeline Therapeutics
Therapeutic Assessment
Cytomegalovirus (CMV) Infection– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
mRNA-1647: ModernaTX, Inc.
Mid Stage Products (Phase II)
Cytomegalovirus vaccine (Triplex): Helocyte
Early Stage Products (Phase I)
VBI-1501: VBI Vaccines Inc.
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Cytomegalovirus (CMV) Infection Key Companies
Cytomegalovirus (CMV) Infection Key Products
Cytomegalovirus (CMV) Infection- Unmet Needs
Cytomegalovirus (CMV) Infection- Market Drivers and Barriers
Cytomegalovirus (CMV) Infection- Future Perspectives and Conclusion
Cytomegalovirus (CMV) Infection Analyst Views
Cytomegalovirus (CMV) Infection Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cytomegalovirus Infection Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

Retinal Vein Occlusion Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Retinal Vein Occlusion Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Retinal Vein Occlusion Treatment Landscape. Click here to read more @ Retinal Vein Occlusion Pipeline Outlook

Key Takeaways from the Retinal Vein Occlusion Pipeline Report

In July 2025, Retina Research Institute LLC announced a clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain. Receive one drop of the topical drops five minutes prior to their regularly scheduled intravitreal injection. Depending on the treatment arm, they will also administer drops on their own at home up to 3 times per day on the day of their procedure.
DelveInsight’s Retinal Vein Occlusion Pipeline analysis depicts the space with 15+ active players working to develop 15+ pipeline therapies.
The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Promising Retinal Vein Occlusion Pipeline Therapies include Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.

For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Drugs Developmental Activities, and News, click here @ Retinal Vein Occlusion Ongoing Clinical Trial Analysis

Retinal Vein Occlusion Emerging Drugs

KSI-301: Kodiak sciences

The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.

601: Sunshine Guojian Pharmaceutical

601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.

IBE-814: Ripple Therapeutics

IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).

The Retinal Vein Occlusion Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion market

Stay informed about the Retinal Vein Occlusion Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Retinal Vein Occlusion Unmet Needs

Retinal Vein Occlusion Companies

Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type

Retinal Vein Occlusion Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Transform your understanding of the Retinal Vein Occlusion Pipeline! See the latest progress in drug development and clinical research @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives

Scope of the Retinal Vein Occlusion Pipeline Report

Coverage- Global
Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
Retinal Vein Occlusion Pipeline Therapies- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.
Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Ophthalmology Research–Access the Full Retinal Vein Occlusion Pipeline Analysis Today! @ Retinal Vein Occlusion Drugs and Companies

Table of Contents

Introduction
Executive Summary
Retinal Vein Occlusion: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
KSI-301: Kodiak sciences
Mid Stage Products (Phase II)
601: Sunshine Guojian Pharmaceutical
Early Stage Products (Phase I)
MHU650: Novartis
Inactive Products
Retinal Vein Occlusion Key Companies
Retinal Vein Occlusion Key Products
Retinal Vein Occlusion- Unmet Needs
Retinal Vein Occlusion- Market Drivers and Barriers
Retinal Vein Occlusion- Future Perspectives and Conclusion
Retinal Vein Occlusion Analyst Views
Retinal Vein Occlusion Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Retinal Vein Occlusion Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

Follicular Lymphoma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request a sample and discover the recent advances in Follicular Lymphoma Treatment Drugs @ Follicular Lymphoma Pipeline Outlook Report

Key Takeaways from the Follicular Lymphoma Pipeline Report

In August 2025, Celgene announced a study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator’s choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
In August 2025, Epizyme, Inc. conducted a study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed.
In August 2025, Hoffmann-La Roche announced a study will evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of mosunetuzumab (Mosun) + lenalidomide (Len) (Mosun + Len) in participants with follicular lymphoma (FL). This study will also compare the pharmacokinetics, pharmacodynamics, safety, efficacy, and immunogenicity of IV mosunetuzumab + len vs subcutaneous (SC) mosunetuzumab + len.
DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 45+ Follicular Lymphoma companies working to develop 50+ pipeline treatment therapies.
The leading Follicular Lymphoma Companies such as Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.
Promising Follicular Lymphoma Pipeline Therapies such as DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.

Find out more about Follicular Lymphoma Therapeutics Assessment @ Follicular Lymphoma Preclinical and Discovery Stage Products

Follicular Lymphoma Emerging Drugs

MIL62: MAB WORKS

MIL62 is a third-generation anti-CD20 antibody with a unique competitive position. MIL62 is the first domestically developed third-generation anti-CD20 antibody entering Phase III registration trial in China. MIL62 is self-developed by leveraging our ADCC-enhanced antibody platform. In in vitro and in vivo studies, MIL62 demonstrates stronger ADCC and anti-tumor activities than rituximab (first-generation anti-CD20 antibodies) and obinutuzumab (other third-generation anti-CD20 antibody). The company is implementing critical clinical development strategies to first pursue marketing approval from the NMPA for the treatment of relapsed and/or refractory FL patients and DLBCL patients. At the same time, MIL62 is being developed for previously untreated FL and DLBCL patients (a significantly larger patient population) by demonstrating clinical superiority over rituximab. Currently the drug is in Phase III stage of its development for the treatment of follicular lymphoma.

AZD0486: AstraZeneca

AZD0486, also known as TNB-486, is an innovative bispecific antibody targeting CD19 and CD3, designed to enhance T-cell-mediated destruction of malignant B cells, particularly in patients with relapsed or refractory follicular lymphoma (FL). AZD0486 functions by engaging T-cells to attack B-cell malignancies, thereby circumventing some limitations associated with traditional therapies. Its design incorporates a low-affinity anti-CD3 moiety, which helps mitigate severe cytokine release syndrome (CRS), a common side effect of T-cell engagers. This unique feature allows for a more controlled immune response, potentially leading to better safety profiles. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Follicular Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (Abx) is a novel, potent, orally administered pan-histone deacetylase inhibitor (HDACi) developed by Xynomic Pharmaceuticals. It is designed to maintain effective anti-tumor concentrations through twice-daily (BID) dosing. Abexinostat targets multiple HDAC enzymes, which are involved in the deacetylation of histones, leading to chromatin remodeling and regulation of gene expression. By inhibiting HDACs, Abexinostat causes the accumulation of acetylated histones, promoting apoptosis, cell cycle arrest, and inhibition of angiogenesis in cancer cells. Additionally, Abexinostat acts as a Rad51 recombinase inhibitor, interfering with DNA repair mechanisms, which enhances its anti-cancer activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Follicular Lymphoma.

ABBV-319: AbbVie

ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to reduce glucocorticoid-associated toxicities while possessing 3 distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of a glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced fragment crystallizable (Fc)–mediated effector function via afucosylation of the antibody backbone. Currently, the drug is in the Phase I stage of development to treat Follicular Lymphoma.

NX-2127: Nurix Therapeutics, Inc.

NX-2127 is an oral small molecule degrader of BTK and cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos). Cereblon immunomodulatory drugs that induce degradation IKZF1 and IKZF3 such as lenalidomide and pomalidomide are FDA approved for a variety of hematologic malignancies including multiple myeloma, follicular lymphoma, and mantle cell lymphoma. We hypothesize that the combination of BTK degradation and cereblon immunomodulatory activity will have enhanced therapeutic benefit in patients suffering from a variety of B-cell malignancies. Initial clinical data support the activity of NX-2127 in patients whose tumors harbor either wild-type BTK or BTK with mutations conferring clinical resistance to FDA approved agents. Initial clinical data also confirm potent BTK degradation with once daily oral dosing. Currently, the drug is in the Phase I stage of its development for the treatment of Follicular Lymphoma.

The Follicular Lymphoma pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Follicular Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Follicular Lymphoma Treatment.
Follicular Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Follicular Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Follicular Lymphoma market.

Explore the dynamic world of drug development with our latest Follicular Lymphoma Pipeline Insights report! Don’t miss this opportunity to stay informed—download now! @ Follicular Lymphoma Treatment Drugs

Follicular Lymphoma Companies

Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.

Follicular Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Follicular Lymphoma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn more about the emerging Follicular Lymphoma Pipeline Therapies @ Follicular Lymphoma Clinical Trials Assessment

Scope of the Follicular Lymphoma Pipeline Report

Coverage- Global
Follicular Lymphoma Companies- Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene and others.
Follicular Lymphoma Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
Follicular Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Follicular Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which Follicular Lymphoma Companies are leading the way in drug discovery? Download now to stay at the forefront of pharmaceutical innovation!” @ Follicular Lymphoma Emerging Drugs and Companies

Table of Contents

Introduction
Executive Summary
Follicular Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Follicular Lymphoma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
MIL62: MAB WORKS
Mid Stage Products (Phase II)
Abexinostat: Xynomic Pharmaceuticals
Early Stage Products (Phase I)
ABBV-319: AbbVie
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
Follicular Lymphoma Key Companies
Follicular Lymphoma Key Products
Follicular Lymphoma- Unmet Needs
Follicular Lymphoma- Market Drivers and Barriers
Follicular Lymphoma- Future Perspectives and Conclusion
Follicular Lymphoma Analyst Views
Follicular Lymphoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Follicular Lymphoma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

Good Dog Academy Leads The Charge With Their How To Become A Dog Trainer Online Program

“A clean, modern illustration shows a woman training a golden-brown dog while seated beside a laptop. She raises a finger in a teaching gesture as the dog sits attentively. Above her, a checkmark in a thought bubble symbolizes success and learning. The title “How to Become a Dog Trainer Online?” appears prominently at the top, reinforcing the theme of virtual certification and professional development in dog training.”

The demand for certified dog trainers is rising, and online programs now make it easier than ever to turn a passion for dogs into a professional career. With flexible, science-based certification courses, aspiring trainers can learn positive reinforcement methods, gain mentorship, and build practical skills from anywhere. Online education provides an accessible path to launching or advancing a career in dog training without the barriers of traditional schooling.

VANCOUVER, BC – August 18, 2025 – Good Dog Academy today announced the launch of its comprehensive online professional dog training certification program, designed specifically for working adults and career-changers seeking to enter the growing field of professional dog training. The program delivers evidence-based, force-free methods through a structured curriculum that includes practical video assessments with instructor feedback, monthly live Q&A sessions, and ongoing post-graduation support.

The innovative online model addresses key barriers that have traditionally limited access to professional dog training education: geographic constraints, high costs, and scheduling inflexibility. By offering 24/7 access to coursework, transparent pricing with financing options, and lifetime access to materials, Good Dog Academy provides a complete alternative to expensive, location-bound traditional programs.

Comprehensive Training with Real-World Application

The curriculum is anchored in modern behavioral science and positive-reinforcement techniques, guiding learners through sequential modules from foundational concepts to real-world scenarios. Core topics include canine body language interpretation, reinforcement strategies, behavior shaping and capturing, problem-solving protocols, client communication, and session planning.

What sets the program apart is its emphasis on practical competency validation. Students submit videos demonstrating their skills, which are reviewed by expert instructors who provide detailed feedback on timing, criteria setting, reinforcement delivery, leash handling, and decision-making processes.

“Our mandate is simple: teach humane, modern training to professional standards and remove the barriers that stop good people from entering the field,” said the Program Director at Good Dog Academy. “Competency requires feedback, practice, and repetition. We built an online cadence that delivers all three, then we extended support after graduation so trainers keep improving while they earn.”

Value-Dense Bundle Expands Career Opportunities

The entry-level program includes not only core trainer certification but also adjacent micro-credentials that significantly expand employability opportunities:

Dog Walking Certification: Safe handling and route planning protocols
Daycare/Boarding Operations: Intake procedures, safety protocols, sanitation standards, and enrichment frameworks
Scent Work Foundations: Techniques for developing canine focus and confidence
Enrichment Design: Customized activities tailored to individual dog energy levels, age, and temperament
Canine First Aid: Emergency response training for field incidents

This comprehensive approach allows graduates to launch solo practices, join pet-care employers with enhanced qualifications, or stack multiple revenue streams while building their client base.

Three Clear Career Pathways

Graduates complete the program with demonstrable skills in humane training mechanics, a comprehensive library of session plans, and a video portfolio ready for client or employer presentation. The program supports three immediate career outcomes:

Independent Practice Launch: Complete with service definitions, pricing frameworks, and marketing toolkit
Employment Enhancement: Qualified for positions in daycare, boarding, shelter, or veterinary settings
Revenue Stream Diversification: Ability to combine training services with walking, enrichment sessions, or daycare work

Post-Graduation Support Sustains Momentum

Recognizing that certification is just the beginning, Good Dog Academy offers an optional Post-Professional Dog Trainer (PPDT) Support Program. This continuing education track provides ongoing mentorship, curriculum updates, refresher training, and business development resources including pricing strategies, service packaging, marketing fundamentals, and client retention methodologies.

Meeting Growing Market Demand

The program addresses surging demand for professional dog trainers while traditional training schools remain expensive and geographically limited. By combining the accessibility of online learning with the rigor of hands-on assessment and mentorship, Good Dog Academy eliminates the traditional trade-off between affordability and educational quality.

The target audience includes aspiring trainers aged 18-55 across North America who prioritize animal welfare, evidence-based methods, and practical skill development. Many are career-changers already working in pet care—dog walkers, daycare staff, and pet sitters—seeking to formalize their skills and expand their service offerings.

About Good Dog Academy

Good Dog Academy provides online, science-based education for aspiring and working dog professionals across North America. The academy’s professional trainer pathway combines self-paced curriculum, practical video assessments, instructor mentorship, and monthly live sessions. Bundled micro-credentials in dog walking, daycare/boarding, enrichment, and scent work expand employability, while an optional post-graduation support program maintains coaching, updates, and business enablement. The model prioritizes force-free, positive-reinforcement methods and is designed to compress time-to-competency without sacrificing standards.

For more information about Good Dog Academy’s online dog trainer certification program, visit https://www.gooddog-academy.com or contact us using the information below.

Media Contact:

Geri Patz, Good Dog Academy, Phone: (604) 537-1721, Email: press@gooddog-academy.com

Media Contact
Company Name: Good Dog Academy
Contact Person: Geri Patz
Email: Send Email
Country: Canada
Website: https://www.gooddog-academy.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Good Dog Academy Leads The Charge With Their How To Become A Dog Trainer Online Program

Smart Separation Expands Family Mediation Services Across the GTA and Vaughan

Smart Separation, Toronto’s smart provider of family mediation and separation solutions, announced today the expansion of its professional services across the Greater Toronto Area (GTA) and Vaughan. Families in Vaughan, Brampton, Mississauga, and Ottawa can now access the same trusted mediation expertise that has made Smart Separation a go-to resource for couples navigating separation and divorce in Ontario.

Founded with the mission of helping families resolve conflicts respectfully and cost-effectively, Smart Separation has become known for its client-centered approach to family mediation. The firm offers personalized solutions designed to reduce conflict, save time, and minimize the financial and emotional toll of traditional litigation. With the expansion into additional cities, Smart Separation is reaffirming its commitment to supporting families across Ontario.

“Our goal has always been to make family mediation more accessible, affordable, and effective for couples who want to separate on good terms,” said Assad Bajwa, founder of Smart Separation and a seasoned divorce mediator. “By extending our services to Vaughan, Brampton, Mississauga, and Ottawa, we can help more families reach fair agreements while keeping the best interests of children at the center of the process.”

A Better Alternative to Court Battles

Family mediation offers couples a private and less adversarial way to address difficult issues such as child custody, parenting arrangements, property division, and financial support. Unlike court proceedings, mediation emphasizes open communication and collaborative problem-solving. This process not only saves families thousands of dollars in legal fees but also allows them to maintain control over the outcome.

At Smart Separation, mediation sessions are tailored to the unique needs of each family. Couples can resolve disputes at their own pace, with the guidance of a neutral and experienced mediator. Services include assistance with separation agreements, parenting plans, uncontested divorce, and other family law matters.

Expansion Driven by Community Demand

The decision to expand beyond Toronto was fueled by growing demand for professional mediation services outside the city core. Many families in surrounding communities face similar challenges but have limited access to specialized mediation. Smart Separation’s expansion bridges this gap, ensuring that families across Vaughan, Brampton, Mississauga, and Ottawa can access high-quality mediation without the stress of prolonged court cases.

“Families in every part of Ontario deserve access to fair, affordable, and compassionate mediation services,” Bajwa added. “We’re proud to bring our expertise to these communities and to continue our mission of reducing conflict and creating healthier outcomes for families.”

About Smart Separation

Smart Separation is a Toronto-based family mediation provider dedicated to helping couples resolve disputes respectfully and efficiently. Specializing in separation agreements, child custody arrangements, and uncontested divorce, the firm empowers families to make informed decisions while avoiding the high costs and conflict of litigation. With a growing presence across Ontario, Smart Separation is committed to supporting families during life’s most difficult transitions.

Media Contact
Company Name: Smart Separation
Contact Person: Assad Bajwa
Email: Send Email
Phone: (416) 820-1264
Address:45 Sheppard Avenue East, Suite 500A
City: Toronto
State: Ontario M2N 5W9
Country: Canada
Website: https://smartseparation.ca/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Smart Separation Expands Family Mediation Services Across the GTA and Vaughan

Dr. Sandra Thompson Offers August Special for New Pediatric Dental Patients in Las Vegas

Award-Winning Pediatric Dentist Dr. Sandra Thompson Invites Las Vegas Families to Experience Exceptional Children’s Dental Care.

Desert Kids Dental, home to Gold Winner for Best Pediatric Dentist in the Best of Las Vegas Magazine, is making quality dental care even more accessible for families this August. The practice is offering a $99 New Patient Special for children, which includes a thorough dental checkup, professional cleaning, and digital X-rays – all performed in a friendly, anxiety-free environment.

Parents are encouraged to take advantage of this limited-time promotion to ensure their child’s smile stays healthy and bright. The offer is available for new patients only and is designed to give families an affordable introduction to Desert Kids Dental’s award-winning services.

Award-Winning Care from Dr. Sandra Thompson

Dr. Sandra Thompson, a highly respected pediatric dentist in Las Vegas, leads the team at Desert Kids Dental. Known for her compassionate approach and commitment to providing pain-free, needle-free care, Dr. Thompson ensures that every child feels comfortable and confident during their visit. Her expertise in pediatric dentistry, combined with a gentle touch, has earned her recognition as one of the top dental professionals in the region.

“We understand that a child’s first dental visit can shape how they feel about oral health for years to come,” said Dr. Thompson. “That’s why we’ve designed our August special to encourage parents to schedule that important first appointment. We want every child to leave our office smiling, knowing that taking care of their teeth can be a positive experience.”

What’s Included in the $99 New Patient Special

The August promotion offers a complete preventive dental package for children:

Comprehensive dental examination – Identifying early signs of cavities, misalignment, and other oral health concerns.
Professional cleaning – Removing plaque and tartar to keep teeth healthy and gums strong.
Digital X-rays – Using advanced imaging for safe, accurate diagnostics.

By bundling these essential services, Desert Kids Dental aims to make preventive care more affordable while reinforcing the importance of regular dental visits.

A Child-Friendly Environment That Reduces Dental Anxiety

Desert Kids Dental is designed with children in mind. From a welcoming atmosphere to kid-friendly technology, the office ensures every patient feels safe and relaxed. The practice also offers sedation-free techniques and gentle treatments that minimize discomfort and help children build trust in their dental care team.

Booking Information

The $99 New Patient Special is available throughout August 2025 and is valid for new patients only. Parents are encouraged to call the office directly to reserve their child’s appointment as spaces are limited.

About Desert Kids Dental

Desert Kids Dental is a leading pediatric dental practice in Las Vegas, Nevada, dedicated to providing high-quality oral health care for infants, children, and teens. Led by Dr. Sandra Thompson, the practice offers a full range of preventive, restorative, and emergency dental services in a welcoming, child-focused environment. With a reputation for compassionate care and advanced techniques, Desert Kids Dental has been recognized as the Gold Winner for Best Pediatric Dentist in the Best of Las Vegas Magazine.

Media Contact
Company Name: Desert Kids Dental
Contact Person: Media Relations
Email: Send Email
Phone: 702-660-7099
Address:9859 W Deer Springs Way STE 110
City: Las Vegas
State: NV 89149
Country: United States
Website: https://www.desertkidsdental.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dr. Sandra Thompson Offers August Special for New Pediatric Dental Patients in Las Vegas

BTL Law Introduces Affordable Basic Prenuptial Agreement Package for Ontario Couples

BTL Law’s Basic Prenup Package offers couples a straightforward marriage contract for $1,500 +HST. Delivered in just five days, it includes spousal support waivers, property division waivers, standard terms, and electronic signing. Ideal for partners with minimal assets, the package provides affordable protection and peace of mind, with a free 15-minute phone consultation available.

BTL Law, a trusted Ontario family law firm, has launched its Basic Prenup Package, offering couples an affordable and efficient way to establish legally binding marriage contracts. Priced at $1,500 plus HST, the package is tailored for partners with minimal assets seeking clarity and protection before marriage.

Prenuptial agreements, formally recognized in Ontario as marriage contracts under the Family Law Act, set out how property, debts, and support will be managed if a marriage ends in separation, divorce, or death. BTL Law’s Basic Prenuptial agreement Package simplifies this process by delivering a clear, professionally drafted contract within just five business days.

“Marriage contracts are about preparation, not pessimism,” said Almas, spokesperson for BTL Law. “With our Basic Prenup Package, couples can protect themselves and avoid uncertainty in the future without going through a complicated or overwhelming process.”

What the Basic Prenup Package Includes

The Basic Prenup Package is designed to be straightforward and cost-effective while ensuring compliance with Ontario law. Each prenuptial agreement is typically 10 pages in length and contains:

Background Section — outlining both partners’ intent and circumstances.
Waivers of Spousal Support — confirming mutual agreement to limit future support claims.
Waivers of Property Division — protecting individual property and minimizing disputes.
Standard General Terms — addressing enforceability, governing law, and dispute resolution.
Electronic Signing — allowing convenient execution without in-person meetings.
Fast Turnaround — delivery in five days or less.

This streamlined offering provides an accessible entry point for couples who do not have extensive or complex financial arrangements but still wish to protect themselves with a valid marriage contract.

Free Consultation Option

To further assist couples considering their options, BTL Law offers a free 15-minute phone consultation. Interested parties can request and book the call online, providing an opportunity to ask preliminary questions and understand whether the Basic Prenup Package is the right fit for their situation.

Legal Safeguards in Ontario

While the Basic Prenup Package covers the essentials, BTL Law also emphasizes the importance of meeting Ontario’s legal requirements:

Prenup agreements must be in writing, signed, and witnessed.
Full financial disclosure is strongly encouraged.
Contracts must be voluntary and fair.
Independent legal advice (ILA) is recommended to enhance enforceability.

Ontario courts may set aside agreements that are unconscionable, signed under duress, or lacking full disclosure. By combining affordability with professional drafting, BTL Law ensures couples receive agreements that are both practical and compliant.

Supporting Couples with Clarity

BTL Law has a strong reputation for guiding clients through family law matters with care and professionalism. The firm’s new package is designed to give everyday couples peace of mind while entering marriage.

“Protecting your future should not be complicated or out of reach,” Almas added. “Our Basic Prenup Package makes it possible for couples to start their married life with security and confidence.”

Media Contact
Company Name: SeparationAgreementOntario Law Firm
Contact Person: Media Relations
Email: Send Email
City: Toronto
State: Ontario
Country: Canada
Website: https://separationagreementontario.ca/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BTL Law Introduces Affordable Basic Prenuptial Agreement Package for Ontario Couples

Felt Right Helps Students and Teachers Prep for the New School Year with Stylish, Sensory-Friendly Wall Solutions

Draper, UT – August 18, 2025 – Felt Right is pleased to announce its back-to-school collection of decorative acoustic felt wall tiles, designed to bring comfort, focus, and creativity to learning spaces everywhere. These versatile wall panels are a must-have for parents, teachers, and students preparing for a fresh academic season.

Felt Right’s signature PET felt tiles combine vibrant design with effective sound-dampening functionality, making them perfect for study corners, bedrooms, classrooms, and homeschool setups. By reducing background noise by up to 35%, these tiles create a calm and focused sensory environment that supports diverse learning needs.

The tiles are made in the USA from recycled plastic bottles and come in a wide range of shapes, colors, and patterns. They easily double as both pinboards and wall décor, providing practical space for schedules, assignments, reminders, or even creative expression. From early education to college-level organization, Felt Right offers tools to help students of all ages stay inspired and on track.

“Back-to-school season is the perfect time to reimagine your space for structure and self-expression,” says Talley Goodson, Founder of Felt Right. “Our acoustic wall tiles are more than decorative, they also help reduce distractions, promote productivity, and support the routines that matter most.”

Whether creating a sensory-conscious study nook or adding a functional design accent to the classroom, Felt Right tiles are easy to install with the included adhesive tabs — no tools, nails, or permanent damage required. They’re lightweight, durable, and ideal for rented spaces and shared environments.

About Felt Right

Design innovator Talley Goodson (founder of 3Form) launched Felt Right to bring sustainable and functional acoustic design into everyday environments. The company transforms recycled plastic waste into beautifully textured felt tiles that blend form, function, and environmental responsibility. Felt Right products help families, students, and professionals design better spaces, one tile at a time.

Explore the full collection at feltright.com.

For Media Inquiries:

Felt Right

801-742-1458

support@feltright.com

https://feltright.com

Media Contact
Company Name: Felt Right
Contact Person: Media Inquiries
Email: Send Email
Phone: 801-742-1458
Country: United States
Website: https://feltright.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Felt Right Helps Students and Teachers Prep for the New School Year with Stylish, Sensory-Friendly Wall Solutions

StockTune Celebrates Creative Milestone by Expanding Free AI Music Collection

StockTune celebrates a creative milestone as it approaches 10,000 monthly visits and tens of thousands of downloads. The AI music platform expands its free collection with new categories, including birthday tracks, gym tunes, victory anthems, music box loops, and Tibetan flutes. Creators now have so many more royalty-free options for every project.

StockTune free AI music for download platform, has hit nearly 10,000 monthly visits, accompanied by tens of thousands of free downloads, a major milestone for the company. To highlight this milestone, the platform has added several new royalty‑free music categories, including birthday tracks, gym tunes, victory anthems, music box loops, and Tibetan flute pieces.

All are still available for free, making StockTune an even more versatile soundtrack resource for creators worldwide.

A Growing Community, A Growing Library

Traffic has surged as creators discover how easy it is to generate background music for videos, apps, podcasts, and presentations. Today’s announcement comes as StockTune’s user base expands and the library grows with it. The latest additions follow already popular genres and bring more mood options to anyone building creative content.

“We saw people using the birthday tracks to surprise friends, and that made us say ‘why stop there?’” said a StockTune team member. “Now you can work on your project without licensing or subscription worries.”

What’s New: More Free Categories for Creators

* Birthday Tracks: Bright, cheerful melodies perfect for personal greetings or festive social media posts.

* Gym Tunes: High-energy beats to match workout videos and motivational scenes.

* Victory Anthems: Triumphant tones for celebratory content in ads, sports highlights, and more.

* Music Box Loops: Gentle, nostalgic loops for intros, vlogs, and ambient scenes.

* Tibetan Flutes: Ethereal, tranquil tracks ideal for playlists, DJs, or calming backgrounds.

Why StockTune Is Different

StockTune isn’t another royalty-free music site. It’s built with AI generation tools that let users customize tone, tempo, or instrumentation before download. All files are royalty-free and public domain, no sampling fees, no legal confusion, no risk.

“Most platforms say ‘choose and pay.’ We just let people choose,” said another StockTune rep. “That simplicity makes people use the tracks, not abandon the project because it’s too complicated.”

StockTune’s engine is built on lightweight AI models that understand what mood creators need. Prompt “energetic gym beat” or “soft birthday melody,” and the tool generates a customizable track instantly. The user may then decide to tweak key elements before downloading.

Every file is quality-checked, tagged accurately, and made available under public domain terms. Data from downloads and genre preferences also helps the system recommend better matches over time.

Impact in Use: Real Projects, Real Creators

* Social posts: Indie creators now pair birthday visuals with matching tracks—no editing suite needed.

* Fitness videos: Gym influencers layer new beats over workout footage, cutting production time in half.

* Marketing highlights: Coaches and gamers use victory anthems to make highlight reels feel more epic.

* Vlogs and podcasts: Store owners and lifestyle creators rely on music box loops to add warmth and polish.

* Meditation and ambient content: The Tibetan flute sounds are already making playlists and relaxation videos richer.

Where StockTune Goes Next

StockTune’s roadmap already includes expanding genres into ambient mixes, holiday jingles, and short game music loops. There’s also a move toward giving creators access to the music engine right in their tools or platforms.

“We’re trying to just give creators what they need, fast,” shared a product developer. “If it helps someone work faster without worrying about licenses, then we’re doing our job.

“All future updates will stay free. We’re simply here to provide more music for anyone who needs it.”

Get Started with StockTune Today

StockTune’s expanded collection is live at stocktune.com. You don’t need an account. If you want mood music, workout beats, or ambient background loops, just browse or search, generate a track, tweak a few settings, then download in high quality.

Contact details:

https://stocktune.com

support@stocktune.com

+48 508 510 740

United States, California

Media Contact
Company Name: StockTune
Contact Person: Fard N
Email: Send Email
Phone: +48 508 510 740
City: San Francisco
State: California
Country: United States
Website: https://stocktune.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: StockTune Celebrates Creative Milestone by Expanding Free AI Music Collection

Cleveland Clinic Welcomes Meditation and Sound Therapy Expert Anthony Profeta to Holistic Health Program

Renowned Practitioner Brings Cutting-Edge Sound Therapy to Cancer Patients

The Cleveland Clinic Florida has tapped renowned meditation teacher and sound therapy specialist Anthony Profeta to join its Holistic Health Program, marking a significant step forward in integrating alternative healing modalities into modern medical care. Profeta, a globally recognized expert in mindfulness, sound healing, and integrative medicine, is now working directly with cancer patients to help manage stress, enhance relaxation, and support their overall well-being through sound bath meditations and individualized therapeutic sessions.

Video Link: https://www.youtube.com/embed/ARTxTwbe5ds

Bridging Ancient Wisdom and Modern Medicine

Profeta’s work is backed by research from the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the American Institute of Stress (AIS), which indicates that up to 90% of all doctor and hospital visits worldwide are stress related. Recognizing the critical role that stress plays in disease and recovery, Cleveland Clinic has embraced meditation and sound therapy as evidence-based tools to support patient outcomes.

“I always knew meditation and sound therapy had the power to heal, but to bring these practices into a leading medical institution like Cleveland Clinic is an incredible full-circle moment for me,” said Profeta. “Twenty years ago, I was on track to become a doctor. Now, I am working in the hospital setting, delivering a different kind of medicine—one that focuses on stress reduction, emotional balance, and whole-person healing.”

The Science Behind Sound Therapy

Profeta’s sound bath therapy sessions at Cleveland Clinic incorporate Tibetan singing bowls, crystal bowls, and harmonic resonance techniques to guide patients into deep relaxation. These methods have been scientifically proven to:

Activate the parasympathetic nervous system, shifting the body out of a stress-induced fight-or-flight state.
Reduce cortisol levels, lowering stress and anxiety.
Enhance sleep quality and pain management, improving overall patient resilience during treatments.

Cleveland Clinic’s decision to integrate sound therapy aligns with a broader movement in modern healthcare, where holistic healing practices are being embraced alongside conventional treatments.

Profeta’s Background and Expertise

With a 25-year career in meditation and holistic health, Profeta has trained under some of the world’s most respected spiritual leaders, including Lama Zopa Rinpoche, the Dalai Lama, and Jack Kornfield. He has also studied sound healing with experts in Nepal, India, and the United States, refining his ability to use vibrational therapy as a tool for deep healing and transformation.

His work has been featured in Huffington Post, Thrive Global, Florida Today, Palm Beach Illustrated, and Vero Beach Magazine. In addition to his work at Cleveland Clinic, he is a featured instructor at the Edgar Cayce Association for Research & Enlightenment (A.R.E.) and leads international retreats in spiritual destinations such as Bali, India, Nepal, and Sedona.

For more information about Anthony Profeta’s work, visit www.AnthonyProfeta.com.

Media Contact
Contact Person: Anthony Profeta
Email: Send Email
Phone: (914) 319-3477
Country: United States
Website: https://www.AnthonyProfeta.com